215 related articles for article (PubMed ID: 12709335)
1. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.
Matar MJ; Ostrosky-Zeichner L; Paetznick VL; Rodriguez JR; Chen E; Rex JH
Antimicrob Agents Chemother; 2003 May; 47(5):1647-51. PubMed ID: 12709335
[TBL] [Abstract][Full Text] [Related]
2. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.
Mandras N; Tullio V; Allizond V; Scalas D; Banche G; Roana J; Robbiano F; Fucale G; Malabaila A; Cuffini AM; Carlone N
Antimicrob Agents Chemother; 2009 Apr; 53(4):1657-9. PubMed ID: 19188375
[TBL] [Abstract][Full Text] [Related]
4. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
[TBL] [Abstract][Full Text] [Related]
6. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
7. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Rinaldi MG; Barnes R; Hu B; Veselov AV; Tiraboschi N; Nagy E; Gibbs DL
J Clin Microbiol; 2005 Dec; 43(12):5848-59. PubMed ID: 16333066
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
Pfaller MA; Diekema DJ; Boyken L; Messer SA; Tendolkar S; Hollis RJ
J Clin Microbiol; 2003 May; 41(5):1875-80. PubMed ID: 12734220
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
10. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of Candida species using the Clinical and Laboratory Standards Institute disk diffusion and broth microdilution methods.
Noake T; Kuriyama T; White PL; Potts AJ; Lewis MA; Williams DW; Barnes RA
J Chemother; 2007 Jun; 19(3):283-7. PubMed ID: 17594923
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
Maxwell MJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Diekema DJ; Pfaller MA
J Clin Microbiol; 2003 Mar; 41(3):1087-90. PubMed ID: 12624034
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
[TBL] [Abstract][Full Text] [Related]
15. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
Kronvall G; Karlsson I
J Clin Microbiol; 2001 Apr; 39(4):1422-8. PubMed ID: 11283066
[TBL] [Abstract][Full Text] [Related]
18. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.
Lozano-Chiu M; Arikan S; Paetznick VL; Anaissie EJ; Rex JH
J Clin Microbiol; 1999 Sep; 37(9):2755-9. PubMed ID: 10449447
[TBL] [Abstract][Full Text] [Related]
19. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates.
Rementeria A; Sanchez-Vargas LO; Villar M; Casals JB; Carrillo-Munoz AJ; Rodriguez Andres C; Eraso E; Quindos G
J Chemother; 2007 Apr; 19(2):172-7. PubMed ID: 17434826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
